Tackling Parkinson's: Pharma Two B tests FDC in Phase IIb
This article was originally published in Scrip
As the world gets ready to mark Parkinson's Disease Awareness Month in April, the harsh reality for patients is the fact there remains no cure and few effective treatments for the chronic, progressive neurological condition, which affects up to one in every 100 people over 60 years.
You may also be interested in...
The Japanese firm's original 2007 NDA was rejected in 2008 but it kept faith in the drug, now approved as an adjunct to levodopa/carbidopa. At least one competitor is waiting in the wings.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.